Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.
Fifteen candidate genetic variants account for only 0.40 percent of variation in opioid use disorder (OUD) risk, according to a study published online Jan. 9 in ...